Oncorena aims to save human lives by transforming a natural substance into a breakthrough treatment for METASTATIC RENAL CANCER.

Read more

Are you or do you have possible candidates for our clinical trials?

We are looking for patients who suffer from metastatic renal cancer and would like to participate in a clinical trial to test a new potential treatment. The objective of the study is to evaluate the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with Metastatic Clear-Cell or Papillary Renal Cell Carcinoma. Find out more about the trial and check your or your candidate’s eligibility here: 

Read more
Alternate Text

Urgent and major unmet medical need


Oncorena breaks new ground in developing an innovative treatment for patients with metastatic renal cancer. About one-third of kidney cancer patients are diagnosed with this fatal disease and...

Building value based on clinical validation


Responding to this challenge, Oncorena is developing a potentially curative treatment based on orellanine, a naturally occurring substance from the Cortinarius family of mushrooms...

Our research makes a difference


Oncorena has completed all preclinical studies and has initiated early-stage clinical development...

Latest Press Release

Oncorena 2023 Team3

Oncorena appoints Susanna Dahlgren as Chief Operating Officer

Susanna Dahlgren now joins Oncorena as Chief Operating Officer, having supported the company for approximately one year as consultant for SDS Life Science -A Cytel Company.

Read more
Jeffrey Yachnin

Oncorena’s First Patient Treated with ONC175 (orellanine) in clinial phase I/II trial  in Patients with Metastatic Renal Cancer and Dialysis at Karolinska University Hospital in Stockholm, Sweden

LUND, SWEDEN, September 4, 2023 – Oncorena announces first patient treated in the Phase I/II trial of the first-in-c…

Read more
Elissa Garcia Ckvjmurwkis Unsplash (1)

Oncorena presents at BioStock Life Science Fall Summit in Lund

Oncorena announces that the company will participate at the BioStock Life Science Fall Summit in Lund, Sweden, on No…

Read more
Pexels Christina Morillo 1181346 (1)

Oncorena expands its management team and strengthens its focus on the company’s initiated clinical Phase I-II study with orellanine

Oncorena AB, which is developing a new and potentially groundbreaking treatment for patients with advanced kidney ca…

Read more

Quick Facts